肺癌患者症状性放射性肺炎预测:基于RTOG 0617与REQUITE的前瞻性多中心影像组学与剂量组学机器学习研究
研究纳入708例多中心肺癌放疗患者(89例发生≥2级症状性放射性肺炎),以RTOG 0617试验441例为训练集、REQUITE研究267例为外部验证集,采用随机森林结合影像组学与剂量组学建模。结果显示整体预测能力有限,最佳影像组学模型测试ROC-AUC为0.56,剂量组学EQD2模型表现受放疗技术影响显著(3D-CRT与IMRT的ROC-AUC分别为0.75与0.39),分技术建模后整体测试ROC-AUC提升至0.61。
要点
- 影像组学与剂量组学模型对症状性放射性肺炎的总体预测能力有限,最佳测试ROC-AUC仅0.56。
- 预测性能高度依赖放疗技术:3D-CRT与IMRT模型表现差异显著。
- 按技术分层建模可改善IMRT的预测,但3D-CRT仍以临床模型更优。
核心结论
- 基于前瞻性试验数据,影像组学和剂量组学模型对症状性放射性肺炎的总体预测能力有限,且受放疗技术影响很大。
- IMRT特异性模型值得进一步研究。
研究设计与样本
- 研究纳入708例多中心肺癌放疗患者,其中89例发生≥2级症状性放射性肺炎。
- 训练集为RTOG 0617前瞻性试验的441例患者,外部验证集为REQUITE前瞻性研究的267例患者。
- 采用随机森林分类器,在10x5折嵌套交叉验证的内层循环中使用最小冗余最大相关算法进行特征选择,并用SMOTE-Tomek处理类别不平衡。
- 以QUANTEC正常组织并发症概率模型作为参照,并按标准/高剂量及3D-CRT/IMRT亚组分层分析。
主要发现
- 嵌套交叉验证中最佳影像组学模型在标准剂量亚组训练,测试ROC-AUC为0.56。
- 基线正常组织并发症概率模型ROC-AUC为0.56,且主要依赖放疗技术(3D-CRT为0.75,IMRT为0.50)。
- 剂量组学EQD2模型在全训练队列训练,在嵌套交叉验证中表现第二,同样呈现技术依赖(ROC-AUC 0.75 vs 0.39)。
- 按3D-CRT和IMRT亚组分别训练的剂量组学EQD2集成模型将整体测试ROC-AUC提升至0.61,在IMRT中优于其他建模策略,但在3D-CRT中不及临床模型。
关键数值与推荐
- 症状性放射性肺炎定义为Common Terminology Criteria for Adverse Events ≥ 2级。
- QUANTEC正常组织并发症概率模型作为参照,其ROC-AUC为0.56(3D-CRT 0.75,IMRT 0.50)。
- 最佳影像组学模型测试ROC-AUC为0.56;剂量组学EQD2模型技术依赖ROC-AUC为0.75 vs 0.39。
- 分技术剂量组学EQD2集成模型整体测试ROC-AUC为0.61。
临床怎么用
- 现有影像组学和剂量组学模型尚不足以可靠预测症状性放射性肺炎以指导治疗修改。
- 建模和预测时应考虑放疗技术的影响,IMRT患者可能需要特异性模型。
- 临床实践中3D-CRT患者可优先参考临床模型,IMRT患者可探索技术特异性剂量组学模型。
局限性
- 影像组学和剂量组学模型的总体预测能力有限,最佳测试ROC-AUC仅0.56。
- 预测性能高度依赖放疗技术,3D-CRT与IMRT模型表现差异大。
- 分技术建模仅在IMRT中优于其他策略,3D-CRT中仍不及临床模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation-induced pneumonitis (RP) is a side effect after thoracic radiation therapy (RT). The ability to predict RP would facilitate treatment modifications. This study investigates the predictive capacity for symptomatic RP (Common Terminology Criteria for Adverse Events ≥ 2) employing Radiomics and Dosiomics models. METHODS AND MATERIALS: Computed tomography scans, along with physical and 2-Gy equivalent dose volumes (EQD2), dose-volume histograms, and clinical parameters, were evaluated for 708 multicenter lung cancer patients, among whom 89 developed RP ≥ 2. The training cohort consisted of 441 patients from the prospective RTOG 0617 trial. External validation was carried out on 267 patients from the prospective REQUITE (validating pREdictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve QUalITy of lifE in cancer survivors) study. A Random Forest classifier was employed, with feature selection executed within the inner loop of a 10x5-fold nested cross-validation (nCV) utilizing the minimum-redundancy-maximum-relevance algorithm. To address class imbalances, synthetic oversampling and undersampling were implemented using SMOTE-Tomek. The QUANTEC Normal Tissue Complication Probability model served as a reference. Additionally, the experiments were stratified by subgroups (standard/high-dose and 3-dimensional conformal RT (3D-CRT)/intensity-modulated RT (IMRT). RESULTS: The best radiomics model identified in the nCV was trained on the standard-dose subgroup achieved a test ROC-AUC of 0.56. The baseline Normal Tissue Complication Probability model showed a predictive performance with a ROC-AUC of 0.56, which was largely dependent on radiation technique (ROC-AUCS: 3D-CRT: 0.75, IMRT: 0.50). The Dosiomics EQD2 model, trained on the full training cohort, attained the second-best performance in the nCV, demonstrating the same technique-dependence (ROC-AUC of 0.75 vs. 0.39). Using a Dosiomics EQD2 ensemble model trained separately on 3D-CRT and IMRT subgroups increased overall performance to a testing ROC-AUC of 0.61, outperforming other modeling strategies for IMRT, while being outperformed by clinical models for 3D-CRT. CONCLUSIONS: This prospective trial-based study reveals an overall limited predictive capacity of radiomics and dosiomics models and a large influence of radiation technique. IMRT-specific models should be investigated further.
引用
- Reuter LM, Kraus KM, Fischer SM, et al. Prediction of Symptomatic Radiation Pneumonitis in Lung Cancer Patients: A Radiomics and Dosiomics Machine Learning Approach Using the Prospective Multicenter RTOG 0617 and REQUITE Trials. Int J Radiat Oncol Biol Phys. 2026. PMID: 41720170. doi:10.1016/j.ijrobp.2026.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。